Association between Markers of Fibrosis and Heart Failure Incidence in Patients with Type 2 Diabetes Mellitus

Type 2 diabetes mellitus (T2DM) and chronic heart failure (HF) have close association, and several biomarkers have been studied to better understand this association and improve prediction of HF in T2DM. Furthermore, in recent clinical trials, sodium glucose cotransporter 2 inhibitors (SGLT2i), gluc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Denis A. Lebedev, Elena A. Lyasnikova, Elena Yu. Vasilyeva, Nikolai P. Likhonosov, Maria Yu. Sitnikova, Alina Yu. Babenko
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/61d19adfbe7947ae91bdf12ab73080bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:61d19adfbe7947ae91bdf12ab73080bc
record_format	dspace
spelling	oai:doaj.org-article:61d19adfbe7947ae91bdf12ab73080bc2021-11-15T01:18:55ZAssociation between Markers of Fibrosis and Heart Failure Incidence in Patients with Type 2 Diabetes Mellitus2314-675310.1155/2021/9589185https://doaj.org/article/61d19adfbe7947ae91bdf12ab73080bc2021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/9589185https://doaj.org/toc/2314-6753Type 2 diabetes mellitus (T2DM) and chronic heart failure (HF) have close association, and several biomarkers have been studied to better understand this association and improve prediction of HF in T2DM. Furthermore, in recent clinical trials, sodium glucose cotransporter 2 inhibitors (SGLT2i), glucose-lowering drugs, improved HF outcomes. The objective of the present study was to evaluate association between circulating biomarkers of fibrosis and incidence of HF with preserved ejection fraction (HFpEF) in patients with T2DM receiving sodium glucose cotransporter 2 inhibitors (SGLT2i). Materials and Methods. At baseline, transthoracic echocardiography and laboratory assessment of N-terminal fragment of the brain natriuretic peptide (Nt-proBNP), soluble suppression of tumorigenesis-2 (sST2), galectin-3 (Gal-3), C-terminal propeptide of procollagen type I (PICP), N-terminal propeptide of procollagen type III (PIIINP), matrix metalloproteinase-9 (MMP-9), and tissue inhibitor of matrix proteinase-1 (TIMP-1) were done. After 3 years of follow-up, information about HF events (hospitalization for HF, established HF in outpatient department by a cardiologist) was obtained. Results. Seventy-two patients were included in the study. The mean age was 57 (49.7; 63.2) years; 44% were female. Most patients had T2DM for more than 4 years. All patients were overweight or had obesity, and 93% patients had arterial hypertension (AH). After 3 years of follow-up, HFpEF was established in 21% patients. Patients were divided into two groups according to the presence of HFpEF, and baseline characteristics were compared. Patients with HF were older and had longer diabetes and AH duration and higher Nt-proBNP, Gal-3, PIIINP, and PICP levels at baseline than patients without HF (all p<0.05). Gal−3>10 ng/ml (OR=2.25; 95% CI, 1.88–5.66; p=0.01) and NT−pro−BNP>80 pg/ml (OR=2.64; 95% CI, 1.56–4.44; p=0.001) were associated with increased risk of HF incidence. Age>60 years, diabetes duration>10 years, and presence of abdominal obesity were independent predictors of HFpEF as well. Conclusions. T2DM patients treated with SLGT2i, who developed HFpEF after 3 years of follow-up, had higher PICP, PIIINP, Gal-3, and NT-proBNP serum concentrations at baseline, and Gal-3 level was an independent predictor of HFpEF.Denis A. LebedevElena A. LyasnikovaElena Yu. VasilyevaNikolai P. LikhonosovMaria Yu. SitnikovaAlina Yu. BabenkoHindawi LimitedarticleDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENJournal of Diabetes Research, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	Diseases of the endocrine glands. Clinical endocrinology RC648-665 Denis A. Lebedev Elena A. Lyasnikova Elena Yu. Vasilyeva Nikolai P. Likhonosov Maria Yu. Sitnikova Alina Yu. Babenko Association between Markers of Fibrosis and Heart Failure Incidence in Patients with Type 2 Diabetes Mellitus
description	Type 2 diabetes mellitus (T2DM) and chronic heart failure (HF) have close association, and several biomarkers have been studied to better understand this association and improve prediction of HF in T2DM. Furthermore, in recent clinical trials, sodium glucose cotransporter 2 inhibitors (SGLT2i), glucose-lowering drugs, improved HF outcomes. The objective of the present study was to evaluate association between circulating biomarkers of fibrosis and incidence of HF with preserved ejection fraction (HFpEF) in patients with T2DM receiving sodium glucose cotransporter 2 inhibitors (SGLT2i). Materials and Methods. At baseline, transthoracic echocardiography and laboratory assessment of N-terminal fragment of the brain natriuretic peptide (Nt-proBNP), soluble suppression of tumorigenesis-2 (sST2), galectin-3 (Gal-3), C-terminal propeptide of procollagen type I (PICP), N-terminal propeptide of procollagen type III (PIIINP), matrix metalloproteinase-9 (MMP-9), and tissue inhibitor of matrix proteinase-1 (TIMP-1) were done. After 3 years of follow-up, information about HF events (hospitalization for HF, established HF in outpatient department by a cardiologist) was obtained. Results. Seventy-two patients were included in the study. The mean age was 57 (49.7; 63.2) years; 44% were female. Most patients had T2DM for more than 4 years. All patients were overweight or had obesity, and 93% patients had arterial hypertension (AH). After 3 years of follow-up, HFpEF was established in 21% patients. Patients were divided into two groups according to the presence of HFpEF, and baseline characteristics were compared. Patients with HF were older and had longer diabetes and AH duration and higher Nt-proBNP, Gal-3, PIIINP, and PICP levels at baseline than patients without HF (all p<0.05). Gal−3>10 ng/ml (OR=2.25; 95% CI, 1.88–5.66; p=0.01) and NT−pro−BNP>80 pg/ml (OR=2.64; 95% CI, 1.56–4.44; p=0.001) were associated with increased risk of HF incidence. Age>60 years, diabetes duration>10 years, and presence of abdominal obesity were independent predictors of HFpEF as well. Conclusions. T2DM patients treated with SLGT2i, who developed HFpEF after 3 years of follow-up, had higher PICP, PIIINP, Gal-3, and NT-proBNP serum concentrations at baseline, and Gal-3 level was an independent predictor of HFpEF.
format	article
author	Denis A. Lebedev Elena A. Lyasnikova Elena Yu. Vasilyeva Nikolai P. Likhonosov Maria Yu. Sitnikova Alina Yu. Babenko
author_facet	Denis A. Lebedev Elena A. Lyasnikova Elena Yu. Vasilyeva Nikolai P. Likhonosov Maria Yu. Sitnikova Alina Yu. Babenko
author_sort	Denis A. Lebedev
title	Association between Markers of Fibrosis and Heart Failure Incidence in Patients with Type 2 Diabetes Mellitus
title_short	Association between Markers of Fibrosis and Heart Failure Incidence in Patients with Type 2 Diabetes Mellitus
title_full	Association between Markers of Fibrosis and Heart Failure Incidence in Patients with Type 2 Diabetes Mellitus
title_fullStr	Association between Markers of Fibrosis and Heart Failure Incidence in Patients with Type 2 Diabetes Mellitus
title_full_unstemmed	Association between Markers of Fibrosis and Heart Failure Incidence in Patients with Type 2 Diabetes Mellitus
title_sort	association between markers of fibrosis and heart failure incidence in patients with type 2 diabetes mellitus
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/61d19adfbe7947ae91bdf12ab73080bc
work_keys_str_mv	AT denisalebedev associationbetweenmarkersoffibrosisandheartfailureincidenceinpatientswithtype2diabetesmellitus AT elenaalyasnikova associationbetweenmarkersoffibrosisandheartfailureincidenceinpatientswithtype2diabetesmellitus AT elenayuvasilyeva associationbetweenmarkersoffibrosisandheartfailureincidenceinpatientswithtype2diabetesmellitus AT nikolaiplikhonosov associationbetweenmarkersoffibrosisandheartfailureincidenceinpatientswithtype2diabetesmellitus AT mariayusitnikova associationbetweenmarkersoffibrosisandheartfailureincidenceinpatientswithtype2diabetesmellitus AT alinayubabenko associationbetweenmarkersoffibrosisandheartfailureincidenceinpatientswithtype2diabetesmellitus
_version_	1718428988435595264

Association between Markers of Fibrosis and Heart Failure Incidence in Patients with Type 2 Diabetes Mellitus

Ejemplares similares